Home/Filings/8-K/0001193125-25-335425
8-K//Current report

Organogenesis Holdings Inc. 8-K

Accession 0001193125-25-335425

$ORGOCIK 0001661181operating

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 4:31 PM ET

Size

219.9 KB

Accession

0001193125-25-335425

Research Summary

AI-generated summary of this filing

Updated

Organogenesis Holdings Inc. Amends Leases, Extends Canton MA Terms to 2032

What Happened

  • Organogenesis Holdings Inc. (through its subsidiary Organogenesis Inc.) announced on December 22, 2025 that it entered into first amendments to two leases for buildings at its Canton, Massachusetts headquarters (65 Dan Road and 150 Dan Road). The lease terms, which otherwise expired December 31, 2027, are extended to December 31, 2032 (Second Renewal Term) with a company option to extend an additional two years to December 31, 2034 (Third Renewal Term). The facilities are used for manufacturing, shipping, operations and research & development. The lease amendment documents are filed as Exhibits 10.1 and 10.2 to the 8-K.

Key Details

  • Original lease expiration: December 31, 2027; amended expiration (Second Renewal Term): December 31, 2032; optional Third Renewal Term to December 31, 2034.
  • 2027 Annual Rent amounts under current leases: $1,608,699.84 (65 Dan Road) and $3,161,377.89 (150 Dan Road).
  • Rent in the first year of the Second Renewal Term will be the greater of 103% of the 2027 Annual Rent and fair market rental value (FMV); thereafter rent increases by 3% annually. The Third Renewal Term uses similar pricing mechanics based on the last year of the Second Renewal Term. An appraisal/arbitration process applies if Organogenesis timely rejects the landlord’s FMV determination.
  • Governance/related-party note: certain landlords (Alan Ades, Albert Erani, Dennis Erani and Glenn Nussdorf) are holders of 5%+ of the Company’s Class A stock and are counterparties; director Glenn Nussdorf and director Robert Ades (son of Alan Ades) were identified. The Audit Committee reviewed and approved the amendments as fair and in the Company’s best interests under the related‑party transactions policy.

Why It Matters

  • The amendments lock in occupancy of Organogenesis’ key manufacturing and R&D facilities for up to nine years (to 2034 if the option is exercised), providing location and operational stability but also creating a long-term fixed-cost commitment for rent.
  • Investors should note the related-party nature of the landlords and that the Audit Committee documented its review and approval; this is relevant for corporate governance and conflicts-of-interest oversight.
  • Material lease terms (rent floors, annual 3% increases, and appraisal/arbitration for FMV) could affect future occupancy costs and cash flow planning; the full amendment texts are available as exhibits to the 8-K for detailed review.